APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

PDC Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PDC Drugs Market Outlook and Growth Opportunities 2026

Report ID 174022780423 December 2025195 pages

Choose your research edition.

Industry ResearchPDC Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal PDC Drugs Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PDC Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PDC Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal PDC Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global PDC Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PDC Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PDC Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PDC Drugs market include Bicycle Therapeutics, Cybrexa Therapeutics, Theratechnologies, Beijing Shenogen Pharma Group, BrightGene Bio-Medical Technology, Gaorui Yaoye(Beijing)Technologies, Shanghai Huiyong Pharmaceutical, Shanghai Pharmaceuticals and Lumosa Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PDC Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PDC Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PDC Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PDC Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

PDC Drugs Segment by Company

Bicycle Therapeutics

Cybrexa Therapeutics

Theratechnologies

Beijing Shenogen Pharma Group

BrightGene Bio-Medical Technology

Gaorui Yaoye(Beijing)Technologies

Shanghai Huiyong Pharmaceutical

Shanghai Pharmaceuticals

Lumosa Therapeutics

Tianjin Conjustar Biotechnology

XINOGEN (HONG KONG) PHARMA

Zhongshan Laibo Ruichen Biopharmaceutical

PDC Drugs Segment by Type

Cell-penetrating Peptides (CPP)

Cell Targeting Peptides (CTP)

Others

PDC Drugs Segment by Application

Breast Cancer

Pancreatic Cancer

Others

PDC Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global PDC Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PDC Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PDC Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze PDC Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PDC Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PDC Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PDC Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PDC Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PDC Drugs industry.

Chapter 3: Detailed analysis of PDC Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PDC Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PDC Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PDC Drugs Industry Trends Table 2. PDC Drugs Industry Drivers Table 3. PDC Drugs Industry Opportunities and Challenges Table 4. PDC Drugs Industry Restraints Table 5. Global PDC Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PDC Drugs Revenue Share by Company (2021-2026) Table 7. Global PDC Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global PDC Drugs Sales Volume Share by Company (2021-2026) Table 9. Global PDC Drugs Average Price (USD/unit) of Company (2021-2026) Table 10. Global PDC Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global PDC Drugs Key Company Manufacturing Base & Headquarters Table 12. Global PDC Drugs Company, Product Type & Application Table 13. Global PDC Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PDC Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cell-penetrating Peptides (CPP) Table 18. Significant Companies of Cell Targeting Peptides (CTP) Table 19. Significant Companies of Others Table 20. Global PDC Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global PDC Drugs Sales Volume by Type (2021-2026) & (k units) Table 22. Global PDC Drugs Sales Volume by Type (2027-2032) & (k units) Table 23. Global PDC Drugs Sales Volume Share by Type (2021-2026) Table 24. Global PDC Drugs Sales Volume Share by Type (2027-2032) Table 25. Global PDC Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global PDC Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global PDC Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global PDC Drugs Sales Value Share by Type (2021-2026) Table 29. Global PDC Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Breast Cancer Table 31. Significant Companies of Pancreatic Cancer Table 32. Significant Companies of Others Table 33. Global PDC Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global PDC Drugs Sales Volume by Application (2021-2026) & (k units) Table 35. Global PDC Drugs Sales Volume by Application (2027-2032) & (k units) Table 36. Global PDC Drugs Sales Volume Share by Application (2021-2026) Table 37. Global PDC Drugs Sales Volume Share by Application (2027-2032) Table 38. Global PDC Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global PDC Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global PDC Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global PDC Drugs Sales Value Share by Application (2021-2026) Table 42. Global PDC Drugs Sales Value Share by Application (2027-2032) Table 43. Global PDC Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global PDC Drugs Sales by Region (2021-2026) & (k units) Table 45. Global PDC Drugs Sales Market Share by Region (2021-2026) Table 46. Global PDC Drugs Sales by Region (2027-2032) & (k units) Table 47. Global PDC Drugs Sales Market Share by Region (2027-2032) Table 48. Global PDC Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global PDC Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global PDC Drugs Sales Value Share by Region (2021-2026) Table 51. Global PDC Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global PDC Drugs Sales Value Share by Region (2027-2032) Table 53. Global PDC Drugs Market Average Price (USD/unit) by Region (2021-2026) Table 54. Global PDC Drugs Market Average Price (USD/unit) by Region (2027-2032) Table 55. Global PDC Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global PDC Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global PDC Drugs Sales by Country (2021-2026) & (k units) Table 58. Global PDC Drugs Sales Market Share by Country (2021-2026) Table 59. Global PDC Drugs Sales by Country (2027-2032) & (k units) Table 60. Global PDC Drugs Sales Market Share by Country (2027-2032) Table 61. Global PDC Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global PDC Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global PDC Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global PDC Drugs Sales Value Market Share by Country (2027-2032) Table 65. Bicycle Therapeutics Company Information Table 66. Bicycle Therapeutics Business Overview Table 67. Bicycle Therapeutics PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 68. Bicycle Therapeutics PDC Drugs Product Portfolio Table 69. Bicycle Therapeutics Recent Development Table 70. Cybrexa Therapeutics Company Information Table 71. Cybrexa Therapeutics Business Overview Table 72. Cybrexa Therapeutics PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. Cybrexa Therapeutics PDC Drugs Product Portfolio Table 74. Cybrexa Therapeutics Recent Development Table 75. Theratechnologies Company Information Table 76. Theratechnologies Business Overview Table 77. Theratechnologies PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Theratechnologies PDC Drugs Product Portfolio Table 79. Theratechnologies Recent Development Table 80. Beijing Shenogen Pharma Group Company Information Table 81. Beijing Shenogen Pharma Group Business Overview Table 82. Beijing Shenogen Pharma Group PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Beijing Shenogen Pharma Group PDC Drugs Product Portfolio Table 84. Beijing Shenogen Pharma Group Recent Development Table 85. BrightGene Bio-Medical Technology Company Information Table 86. BrightGene Bio-Medical Technology Business Overview Table 87. BrightGene Bio-Medical Technology PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. BrightGene Bio-Medical Technology PDC Drugs Product Portfolio Table 89. BrightGene Bio-Medical Technology Recent Development Table 90. Gaorui Yaoye(Beijing)Technologies Company Information Table 91. Gaorui Yaoye(Beijing)Technologies Business Overview Table 92. Gaorui Yaoye(Beijing)Technologies PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Gaorui Yaoye(Beijing)Technologies PDC Drugs Product Portfolio Table 94. Gaorui Yaoye(Beijing)Technologies Recent Development Table 95. Shanghai Huiyong Pharmaceutical Company Information Table 96. Shanghai Huiyong Pharmaceutical Business Overview Table 97. Shanghai Huiyong Pharmaceutical PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Shanghai Huiyong Pharmaceutical PDC Drugs Product Portfolio Table 99. Shanghai Huiyong Pharmaceutical Recent Development Table 100. Shanghai Pharmaceuticals Company Information Table 101. Shanghai Pharmaceuticals Business Overview Table 102. Shanghai Pharmaceuticals PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. Shanghai Pharmaceuticals PDC Drugs Product Portfolio Table 104. Shanghai Pharmaceuticals Recent Development Table 105. Lumosa Therapeutics Company Information Table 106. Lumosa Therapeutics Business Overview Table 107. Lumosa Therapeutics PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. Lumosa Therapeutics PDC Drugs Product Portfolio Table 109. Lumosa Therapeutics Recent Development Table 110. Tianjin Conjustar Biotechnology Company Information Table 111. Tianjin Conjustar Biotechnology Business Overview Table 112. Tianjin Conjustar Biotechnology PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Tianjin Conjustar Biotechnology PDC Drugs Product Portfolio Table 114. Tianjin Conjustar Biotechnology Recent Development Table 115. XINOGEN (HONG KONG) PHARMA Company Information Table 116. XINOGEN (HONG KONG) PHARMA Business Overview Table 117. XINOGEN (HONG KONG) PHARMA PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. XINOGEN (HONG KONG) PHARMA PDC Drugs Product Portfolio Table 119. XINOGEN (HONG KONG) PHARMA Recent Development Table 120. Zhongshan Laibo Ruichen Biopharmaceutical Company Information Table 121. Zhongshan Laibo Ruichen Biopharmaceutical Business Overview Table 122. Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Product Portfolio Table 124. Zhongshan Laibo Ruichen Biopharmaceutical Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. PDC Drugs Distributors List Table 128. PDC Drugs Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. PDC Drugs Product Image Figure 2. Global PDC Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PDC Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global PDC Drugs Sales (2021-2032) & (k units) Figure 5. Global PDC Drugs Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global PDC Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cell-penetrating Peptides (CPP) Image Figure 10. Cell Targeting Peptides (CTP) Image Figure 11. Others Image Figure 12. Global PDC Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global PDC Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global PDC Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global PDC Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global PDC Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global PDC Drugs Sales Value Share by Type (2021-2032) Figure 18. Breast Cancer Image Figure 19. Pancreatic Cancer Image Figure 20. Others Image Figure 21. Global PDC Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global PDC Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global PDC Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global PDC Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global PDC Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global PDC Drugs Sales Value Share by Application (2021-2032) Figure 27. Global PDC Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global PDC Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global PDC Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global PDC Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America PDC Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America PDC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe PDC Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe PDC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific PDC Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific PDC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America PDC Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America PDC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa PDC Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa PDC Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt PDC Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt PDC Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt PDC Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. PDC Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. PDC Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Cell-penetrating Peptides (CPP)
  • Cell Targeting Peptides (CTP)
  • Others
Applications
  • Breast Cancer
  • Pancreatic Cancer
  • Others
Companies covered
  • Bicycle Therapeutics
  • Cybrexa Therapeutics
  • Theratechnologies
  • Beijing Shenogen Pharma Group
  • BrightGene Bio-Medical Technology
  • Gaorui Yaoye(Beijing)Technologies
  • Shanghai Huiyong Pharmaceutical
  • Shanghai Pharmaceuticals
  • Lumosa Therapeutics
  • Tianjin Conjustar Biotechnology
  • XINOGEN (HONG KONG) PHARMA
  • Zhongshan Laibo Ruichen Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PDC Drugs Sales Value (2021-2032)
  4. 1.2.2 Global PDC Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global PDC Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PDC Drugs Market Dynamics
  1. 2.1 PDC Drugs Industry Trends
  2. 2.2 PDC Drugs Industry Drivers
  3. 2.3 PDC Drugs Industry Opportunities and Challenges
  4. 2.4 PDC Drugs Industry Restraints
3 PDC Drugs Market by Company
  1. 3.1 Global PDC Drugs Company Revenue Ranking in 2025
  2. 3.2 Global PDC Drugs Revenue by Company (2021-2026)
  3. 3.3 Global PDC Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global PDC Drugs Average Price by Company (2021-2026)
  5. 3.5 Global PDC Drugs Company Ranking (2024-2026)
  6. 3.6 Global PDC Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global PDC Drugs Company Product Type and Application
  8. 3.8 Global PDC Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PDC Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PDC Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PDC Drugs Market by Type
  1. 4.1 PDC Drugs Type Introduction
  2. 4.1.1 Cell-penetrating Peptides (CPP)
  3. 4.1.2 Cell Targeting Peptides (CTP)
  4. 4.1.3 Others
  5. 4.2 Global PDC Drugs Sales Volume by Type
  6. 4.2.1 Global PDC Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PDC Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global PDC Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global PDC Drugs Sales Value by Type
  10. 4.3.1 Global PDC Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PDC Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global PDC Drugs Sales Value Share by Type (2021-2032)
5 PDC Drugs Market by Application
  1. 5.1 PDC Drugs Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Pancreatic Cancer
  4. 5.1.3 Others
  5. 5.2 Global PDC Drugs Sales Volume by Application
  6. 5.2.1 Global PDC Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PDC Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global PDC Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global PDC Drugs Sales Value by Application
  10. 5.3.1 Global PDC Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PDC Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global PDC Drugs Sales Value Share by Application (2021-2032)
6 PDC Drugs Regional Sales and Value Analysis
  1. 6.1 Global PDC Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PDC Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global PDC Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global PDC Drugs Sales by Region (2027-2032)
  5. 6.3 Global PDC Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PDC Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global PDC Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global PDC Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global PDC Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PDC Drugs Sales Value (2021-2032)
  12. 6.6.2 North America PDC Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PDC Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe PDC Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PDC Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PDC Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PDC Drugs Sales Value (2021-2032)
  21. 6.9.2 South America PDC Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PDC Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PDC Drugs Sales Value Share by Country, 2025 VS 2032
7 PDC Drugs Country-level Sales and Value Analysis
  1. 7.1 Global PDC Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PDC Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PDC Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global PDC Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global PDC Drugs Sales by Country (2027-2032)
  6. 7.4 Global PDC Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global PDC Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global PDC Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PDC Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PDC Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PDC Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PDC Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PDC Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PDC Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PDC Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PDC Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PDC Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PDC Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PDC Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PDC Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PDC Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PDC Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PDC Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PDC Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PDC Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PDC Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PDC Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PDC Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PDC Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PDC Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PDC Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PDC Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PDC Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PDC Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PDC Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PDC Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PDC Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PDC Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PDC Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PDC Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PDC Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PDC Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PDC Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PDC Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PDC Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PDC Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PDC Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PDC Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PDC Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PDC Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PDC Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PDC Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PDC Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PDC Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PDC Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PDC Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PDC Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PDC Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PDC Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PDC Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PDC Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PDC Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PDC Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PDC Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PDC Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PDC Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PDC Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PDC Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PDC Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PDC Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PDC Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PDC Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PDC Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PDC Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PDC Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PDC Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PDC Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PDC Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PDC Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PDC Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PDC Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PDC Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PDC Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PDC Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PDC Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PDC Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PDC Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PDC Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PDC Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PDC Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PDC Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PDC Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bicycle Therapeutics
  2. 8.1.1 Bicycle Therapeutics Company Information
  3. 8.1.2 Bicycle Therapeutics Business Overview
  4. 8.1.3 Bicycle Therapeutics PDC Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bicycle Therapeutics PDC Drugs Product Portfolio
  6. 8.1.5 Bicycle Therapeutics Recent Developments
  7. 8.2 Cybrexa Therapeutics
  8. 8.2.1 Cybrexa Therapeutics Company Information
  9. 8.2.2 Cybrexa Therapeutics Business Overview
  10. 8.2.3 Cybrexa Therapeutics PDC Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cybrexa Therapeutics PDC Drugs Product Portfolio
  12. 8.2.5 Cybrexa Therapeutics Recent Developments
  13. 8.3 Theratechnologies
  14. 8.3.1 Theratechnologies Company Information
  15. 8.3.2 Theratechnologies Business Overview
  16. 8.3.3 Theratechnologies PDC Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Theratechnologies PDC Drugs Product Portfolio
  18. 8.3.5 Theratechnologies Recent Developments
  19. 8.4 Beijing Shenogen Pharma Group
  20. 8.4.1 Beijing Shenogen Pharma Group Company Information
  21. 8.4.2 Beijing Shenogen Pharma Group Business Overview
  22. 8.4.3 Beijing Shenogen Pharma Group PDC Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Beijing Shenogen Pharma Group PDC Drugs Product Portfolio
  24. 8.4.5 Beijing Shenogen Pharma Group Recent Developments
  25. 8.5 BrightGene Bio-Medical Technology
  26. 8.5.1 BrightGene Bio-Medical Technology Company Information
  27. 8.5.2 BrightGene Bio-Medical Technology Business Overview
  28. 8.5.3 BrightGene Bio-Medical Technology PDC Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BrightGene Bio-Medical Technology PDC Drugs Product Portfolio
  30. 8.5.5 BrightGene Bio-Medical Technology Recent Developments
  31. 8.6 Gaorui Yaoye(Beijing)Technologies
  32. 8.6.1 Gaorui Yaoye(Beijing)Technologies Company Information
  33. 8.6.2 Gaorui Yaoye(Beijing)Technologies Business Overview
  34. 8.6.3 Gaorui Yaoye(Beijing)Technologies PDC Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Gaorui Yaoye(Beijing)Technologies PDC Drugs Product Portfolio
  36. 8.6.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
  37. 8.7 Shanghai Huiyong Pharmaceutical
  38. 8.7.1 Shanghai Huiyong Pharmaceutical Company Information
  39. 8.7.2 Shanghai Huiyong Pharmaceutical Business Overview
  40. 8.7.3 Shanghai Huiyong Pharmaceutical PDC Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shanghai Huiyong Pharmaceutical PDC Drugs Product Portfolio
  42. 8.7.5 Shanghai Huiyong Pharmaceutical Recent Developments
  43. 8.8 Shanghai Pharmaceuticals
  44. 8.8.1 Shanghai Pharmaceuticals Company Information
  45. 8.8.2 Shanghai Pharmaceuticals Business Overview
  46. 8.8.3 Shanghai Pharmaceuticals PDC Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai Pharmaceuticals PDC Drugs Product Portfolio
  48. 8.8.5 Shanghai Pharmaceuticals Recent Developments
  49. 8.9 Lumosa Therapeutics
  50. 8.9.1 Lumosa Therapeutics Company Information
  51. 8.9.2 Lumosa Therapeutics Business Overview
  52. 8.9.3 Lumosa Therapeutics PDC Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Lumosa Therapeutics PDC Drugs Product Portfolio
  54. 8.9.5 Lumosa Therapeutics Recent Developments
  55. 8.10 Tianjin Conjustar Biotechnology
  56. 8.10.1 Tianjin Conjustar Biotechnology Company Information
  57. 8.10.2 Tianjin Conjustar Biotechnology Business Overview
  58. 8.10.3 Tianjin Conjustar Biotechnology PDC Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tianjin Conjustar Biotechnology PDC Drugs Product Portfolio
  60. 8.10.5 Tianjin Conjustar Biotechnology Recent Developments
  61. 8.11 XINOGEN (HONG KONG) PHARMA
  62. 8.11.1 XINOGEN (HONG KONG) PHARMA Company Information
  63. 8.11.2 XINOGEN (HONG KONG) PHARMA Business Overview
  64. 8.11.3 XINOGEN (HONG KONG) PHARMA PDC Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 XINOGEN (HONG KONG) PHARMA PDC Drugs Product Portfolio
  66. 8.11.5 XINOGEN (HONG KONG) PHARMA Recent Developments
  67. 8.12 Zhongshan Laibo Ruichen Biopharmaceutical
  68. 8.12.1 Zhongshan Laibo Ruichen Biopharmaceutical Company Information
  69. 8.12.2 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
  70. 8.12.3 Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zhongshan Laibo Ruichen Biopharmaceutical PDC Drugs Product Portfolio
  72. 8.12.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PDC Drugs Value Chain Analysis
  2. 9.1.1 PDC Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PDC Drugs Sales Mode & Process
  6. 9.2 PDC Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PDC Drugs Distributors
  9. 9.2.3 PDC Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst